ISSN: 1837-9664Journal of Cancer
Global reach, higher impact
J Cancer 2023; 14(13):2455-2467. doi:10.7150/jca.83708 This issue Cite
Research Paper
SIK1 suppresses colorectal cancer metastasis and chemoresistance via the TGF-β signaling pathway
1. The Second School of Clinical Medicine, Southern Medical University, Guangzhou 510000, China.
2. Department of Gastrointestinal Surgery, Department of General Surgery, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou 510000, China.
3. Department of General Surgery, Guangdong Provincial People's Hospital Ganzhou Hospital (Ganzhou Municipal Hospital), Ganzhou, 341000, China.
4. Department of Colorectal surgery, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, 510120, China.
#These authors contributed equally to this work.
Citation:
Gao Y, Li H, Wang P, Wang J, Yao X. SIK1 suppresses colorectal cancer metastasis and chemoresistance via the TGF-β signaling pathway. J Cancer 2023; 14(13):2455-2467. doi:10.7150/jca.83708. https://www.jcancer.org/v14p2455.htm
Other stylesAbstract
In the present study, we investigated the role of salt-induced kinase 1 (SIK1), a serine/threonine kinase protein, in colorectal cancer (CRC). Despite the reported association of SIK1 with tumor malignancy suppression in various cancers, limited research has been conducted on its function in CRC. Our findings revealed that SIK1 expression was low in CRC cells. The results of a KEGG pathway analysis showed a strong association between SIK1 and the TGF-β signaling pathway. In addition, a coimmunoprecipitation assay validated the interaction between SIK1 and Smad7. Our data indicate that SIK1 inhibited the phosphorylation of Smad2, a critical molecule in the Smad-related TGF-β pathway, and downstream target genes of the TGF-β pathway. Furthermore, SIK1 was found to inhibit indicators of epithelial-mesenchymal transition (EMT) and reverse oxaliplatin resistance in CRC. Additionally, SIK1 reduced cell migration and invasion. Our results suggest that the inhibitory effect of SIK1 on the TGF-β pathway contributes to the suppression of metastasis and oxaliplatin chemoresistance in CRC. However, this effect was reversed by galunisertib (LY2157299). In conclusion, our findings provide novel insights into the role of SIK1 in the regulation of the TGF-β pathway in CRC, suggesting its potential as a therapeutic target for the treatment of CRC. Further studies are required to fully characterize the mechanism underlying these observations and to validate these findings in animal models.
Keywords: salt-induced kinase 1 (SIK1), colorectal cancer, TGF-β/Smad signaling pathway, epithelial-mesenchymal transition, oxaliplatin resistance
Citation styles
APA
Gao, Y., Li, H., Wang, P., Wang, J., Yao, X. (2023). SIK1 suppresses colorectal cancer metastasis and chemoresistance via the TGF-β signaling pathway. Journal of Cancer, 14(13), 2455-2467. https://doi.org/10.7150/jca.83708.
ACS
Gao, Y.; Li, H.; Wang, P.; Wang, J.; Yao, X. SIK1 suppresses colorectal cancer metastasis and chemoresistance via the TGF-β signaling pathway. J. Cancer 2023, 14 (13), 2455-2467. DOI: 10.7150/jca.83708.
NLM
Gao Y, Li H, Wang P, Wang J, Yao X. SIK1 suppresses colorectal cancer metastasis and chemoresistance via the TGF-β signaling pathway. J Cancer 2023; 14(13):2455-2467. doi:10.7150/jca.83708. https://www.jcancer.org/v14p2455.htm
CSE
Gao Y, Li H, Wang P, Wang J, Yao X. 2023. SIK1 suppresses colorectal cancer metastasis and chemoresistance via the TGF-β signaling pathway. J Cancer. 14(13):2455-2467.
This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.